AbbVie Inc. (NYSE: ABBV)
Hagens Berman Sobol Shapiro LLP reminds investors in AbbVie Inc. (NYSE: ABBV) of the November 20, 2018 Lead Plaintiff deadline in the securities class action pending in the United States District Court for the Central District of California.
If you purchased or otherwise acquired AbbVie securities between November 18, 2017 and September 17, 2018 and suffered losses contact Hagens Berman Sobol Shapiro LLP. For more infomation contact Reed Kathrein, who is leading the firm's investigation, by calling 510-725-3000 or emailing ABBV@hbsslaw.com.
On September 18, 2018, Bloomberg reported California’s insurance regulator is suing AbbVie, alleging that the Company gave illegal kickbacks to health-care providers in order to keep patients on its blockbuster rheumatoid arthritis drug Humira.
The California Department of Insurance accuses Abbvie of engaging “in a far-reaching scheme including both classic kickbacks – cash, meals, drinks, gifts, trips, and patient referrals – and more sophisticated ones – free and valuable professional goods and services to physicians to induce and reward Humira prescriptions.”
This news drove the price of AbbVie shares down $2.76 to close at $92.61 on September 18, 2018.
“We’re focused on investors’ losses and whether Defendants’ statements about AbbVie’s revenues and business practices were misleading,” said Hagens Berman partner Reed Kathrein.
Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.